Summary
Bristol-Myers Squibb Company (BMY) has filed an 8-K report on July 26, 2024, to announce its financial results for the second quarter of 2024. The report primarily references an Earnings Press Release and a related Investor Presentation, both dated July 26, 2024, which contain detailed financial and operational information. Investors should refer to these furnished documents for a comprehensive understanding of the company's performance during the quarter. The company has made these materials available on its website and through a conference call and webcast. It's important for investors to note that both the press release and presentation include non-GAAP financial information. The company has provided reconciliations between non-GAAP and GAAP measures within the Earnings Press Release, along with explanations for the use of these non-GAAP figures. Investors are advised to review these reconciliations and the company's official filings for complete financial transparency.
Key Highlights
- 1BMY filed an 8-K on July 26, 2024, to report Q2 2024 financial results.
- 2Key financial and operational details are provided in an Earnings Press Release (Exhibit 99.1).
- 3An Investor Presentation (Exhibit 99.2) offering further insights into financial and operating initiatives is also available.
- 4Both the press release and presentation contain non-GAAP financial information.
- 5Reconciliations between non-GAAP and GAAP financial measures are available in the Earnings Press Release.
- 6The furnished information is not deemed 'filed' under Section 18 of the Exchange Act, meaning it does not carry the same legal implications as traditional filings.
- 7BMY hosted a conference call and webcast on July 26, 2024, to discuss the Q2 results and presentation.